Serum infliximab levels and clinical response in hidradenitis suppurativa

Serum infliximab levels and clinical response in hidradenitis suppurativa

Abstract Background Infliximab (IFX) is a chimeric immunoglobulin G‐1κ monoclonal antibody that neutralises the biologic activity of tumour necrosis factor‐α, and has shown efficacy (off‐label) for the treatment of severe hidradenitis suppurativa (HS). The relationship between clinical response and...

Full description

Bibliographic Details
Main Authors: Erwin Benassaia, Jean‐David Bouaziz, Marie Jachiet, Florence Cordoliani, Anne Saussine, Clemence Lepelletier, Lauriane Goldwirt, Charles Cassius, Adèle deMasson, Martine Bagot, Hervé Bachelez, Florence Assan
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:JEADV Clinical Practice
Subjects:
hidradenitis suppurativa
HiSCR
infliximab
therapeutic drug monitoring
trough serum infliximab
Online Access:https://doi.org/10.1002/jvc2.139

Internet

https://doi.org/10.1002/jvc2.139

Similar Items